Suppression of the immune response to an adenovirus vector and enhancement of intratumoral transgene expression by low-dose etoposide

Gene Therapy

Volumn 5, Issue 2, 1998, Pages 189-195

  Bouvet, M ^a   Fang, B ^a   Ekmekcioglu, S ^a   Ji, L ^b   Bucana, C D ^a   Hamada, K ^c   Grimm, E A ^a   Roth, J A ^a,d  

^a UNIVERSITY OF TEXAS   (United States)

^b Introgen Therapeutics Inc   (United States)

^c EHIME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Cancer gene therapy; Cyclophosphamide; Cytotoxic T lymphocytes; Etoposide; Neutralizing antibodies

Indexed keywords

CYCLOPHOSPHAMIDE; ETOPOSIDE; NEUTRALIZING ANTIBODY; VIRUS VECTOR;

ADENOVIRUS; ANIMAL CELL; ARTICLE; CANCER; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; FEMALE; GENE EXPRESSION; GENE THERAPY; GENE TRANSFER; GENETIC TRANSDUCTION; HUMORAL IMMUNITY; IMMUNOSUPPRESSIVE TREATMENT; LYSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANSGENE;

ADENOVIRIDAE; ANIMALIA;

EID: 0031911004     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3300564     Document Type: Article

References (26)

1. Roth JA, Cristiano RJ. Gene therapy for cancer: what have we done and where are we going? J Natl Cancer Inst 1997; 89: 21-39.
2. Zhang WW et al. High-efficiency gene transfer and high-level expression of wild-type p53 in human lung cancer cells mediated by recombinant adenovirus. Cancer Gene Ther 1994; 1: 5-13.
3. Zhang WW et al. Generation and identification of recombinant adenovirus by lipsome-mediated transfection and PCR analysis. Biotechniques 1993; 15: 868-872.
4. Spitz FR et al. In vivo adenovirus-mediated p53 tumor suppressor gene therapy for colorectal cancer. Anticancer Res 1996; 16: 3415-3422
5. Liu TJ et al. Apoptosis induction mediated by wild-type p53 adenoviral gene transfer in squamous cell carcinoma of the head and neck. Cancer Res 1995; 55: 3117-3122.
6. Engelhardt JF, Ye XH, Doranz B, Wilson JM. Ablation of E2A in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver. Proc Natl Acad Sci USA 1994; 91: 6196-6200.
7. Yang Y, Li Q, Ertl HC, Wilson JM. Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses. J Virol 1995; 69: 2004-2015.
8. Dai F et al. Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: tolerization of factor IX and vector antigens allows for long-term expression. Proc Natl Acad Sci USA 1995; 92: 1401-1405.
9. Fang B et al. Gene therapy for hemophilia B. host immunosuppression prolongs the therapeutic effect of adenovirus-mediated factor IX expression. Hum Gene Ther 1995; 6: 1039-1044.
10. Kay M et al. Long-term hepatic adenovirus-mediated gene expression in mice following CTLA4-lg administration. Nat Genet 1995; 11: 191-197.
11. Yang Y, Trinchieri G, Wilson JM. Recombinant IL-12 prevents formation of blocking IgA antibodies to recombinant adenovirus and allows repeated gene therapy to mouse lung. Nature Med 1995; 1: 890-893.
12. Jooss K, Yang Y, Wilson JM. Cyclophosphamide diminishes inflammation and prolongs transgene expression following delivery of adenoviral vectors to mouse liver and lung. Hum Gene Ther 1996; 7: 1555-1566.
13. Grunberg SM et al. Extended administration of oral etoposide and oral cyclophosphamide for the treatment of advanced non-small cell lung cancer: a Southwest Oncology Group study. J Clin Oncol 1993; 11: 1598-1601.
14. Yang L, Rowe TC, Liu LF. Identification of DNA topoisomerase II as an intracellular target of antitumor epipodophyllotoxins in simian virus 40-infected monkey cells. Cancer Res 1985; 43: 120-124
15. Lock RB, Stribinskine L. Dual modes of death induced by etoposide in human epithelial tumor cells allow Bcl-2 to inhibit apoptosis without affecting clonogenic survival Cancer Res 1996; 56: 4006-4012.
16. Pommier Y, Fesen MR, Goldwasser F. Topoisomerase II inhibitors: the epipodophyllotoxins, m-AMSA and the ellipticine derivative. In: Chabner BA, Longo DL (eds). Cancer Chemotherapy and Biotherapy, Principles and Practice Lippincott-Raven: Philadelphia, 1996, pp 435-461.
17. Estape J et al. Chronic oral etoposide in non-small cell lung carcinoma. Eur J Cancer 1992; 28: 835-837.
18. Fujiwara Y et al. Bioavailability of 50- and 75-mg oral etoposide in lung cancer patients. Cancer Chemother Pharmacol 1996; 37: 327-331.
19. 2 to M transition: implications for gene therapy. Cancer Res 1997; 57: 818-823.
20. Kripke ML. Latency, histology, and antigenicity of rumors induced by ultraviolet light in three inbred mouse strains. Cancer Res 1977; 37: 1395-1400.
21. Takahashi T et al. p53: A frequent target for genetic abnormalities in lung cancer. Science 1989; 246: 491-494.
22. Graham F, Prevec L. Manipulation of adenovirus vectors. In: Murray EJ (ed). Methods in Molecular Biology: Gene Transfer and Expression Protocols 7. Humana Press: Clifton, NJ, 1991, pp 205-225.
23. Zhang WW et al. Safety evaluation of Ad5CMV-p53 in vitro and in vivo Hum Gene Ther 1995; 6: 155-164
24. Pierceall WE, Kripke ML, Ananthaswamy HN. N-ras mutations in ultraviolet radiation-induced murine skin cancers. Cancer Res 1992; 52: 3946-3951.
25. Kanjilal S et al High frequency of p53 mutations in ultraviolet radiation-induced murine skin tumors: evidence for strand bias and tumor heterogeneity Cancer Res 1993; 53: 2961-2964.
26. Boviatsis EJ et al. Gene transfer into experimental brain tumors mediated by adenovirus. Herpes simplex virus, and retrovirus. Hum Gene Ther 1994; 5: 183-191.